Incretin-based drugs (GLP-1 agonists, DPP-4 inhibitors) combine effectively with metformin, sulfonylureas, and insulin for type 2 diabetes, with optimal pairing depending on patient characteristics and treatment goals.
Key findingGLP-1 agonists and DPP-4 inhibitors combine synergistically with metformin (first-line), sulfonylureas, thiazolidinediones, and insulin for T2DM, with
What the researchers found
GLP-1 agonists and DPP-4 inhibitors combine synergistically with metformin (first-line), sulfonylureas, thiazolidinediones, and insulin for T2DM, with combination selection guided by patient weight, hypo risk, and HbA1c target — practical combination pharmacotherapy guidance.
Why it matters
Relevant for glp-1, diabetes.
How the study worked
review study.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Combination pharmacotherapy with incretins: what works best and when?
Current diabetes reports, 8(5), 361-7
Citation
Over, Rebecca K; Ratner, Robert E. (2008). Combination pharmacotherapy with incretins: what works best and when?. Current diabetes reports, 8(5), 361-7.